305 related articles for article (PubMed ID: 15570574)
61. Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome.
Ikawa M; Yamada K
Clin Neuropharmacol; 2010 May; 33(3):163-4. PubMed ID: 20173629
[TBL] [Abstract][Full Text] [Related]
62. [New drug therapy of adult attention deficit hyperactivity disorder--evaluation of efficacy of milnacipran].
Masuko H
Seishin Shinkeigaku Zasshi; 2008; 110(10):908-11. PubMed ID: 19278066
[No Abstract] [Full Text] [Related]
63. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
Yoshida K; Takahashi H; Higuchi H; Kamata M; Ito K; Sato K; Naito S; Shimizu T; Itoh K; Inoue K; Suzuki T; Nemeroff CB
Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646
[TBL] [Abstract][Full Text] [Related]
64. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures.
Yeragani VK; Pesce V; Jayaraman A; Roose S
Biol Psychiatry; 2002 Sep; 52(5):418-29. PubMed ID: 12242058
[TBL] [Abstract][Full Text] [Related]
65. Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts.
Fava GA
Psychother Psychosom; 1995; 64(2):57-61. PubMed ID: 8559954
[No Abstract] [Full Text] [Related]
66. [Withdrawal syndrome after the use of serotonin reuptake inhibitors].
Fagan M
Tidsskr Nor Laegeforen; 2000 Mar; 120(8):913-4. PubMed ID: 10795494
[TBL] [Abstract][Full Text] [Related]
67. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
[TBL] [Abstract][Full Text] [Related]
68. An overview of the clinical efficacy of mirtazapine.
Benkert O; Muller M; Szegedi A
Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S23-6. PubMed ID: 12404666
[TBL] [Abstract][Full Text] [Related]
69. [Withdrawal symptoms in connection with the use of selective serotonin reuptake inhibitors (SSRI)].
Gram LF
Ugeskr Laeger; 1998 Dec; 160(50):7291-3. PubMed ID: 9859737
[No Abstract] [Full Text] [Related]
70. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
71. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
Arnold LM; Bateman L; Palmer RH; Lin Y
Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278
[TBL] [Abstract][Full Text] [Related]
72. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
[TBL] [Abstract][Full Text] [Related]
73. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
[TBL] [Abstract][Full Text] [Related]
74. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y
Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
[TBL] [Abstract][Full Text] [Related]
75. [Withdrawal syndrome caused by selective serotonin reuptake inhibitors: apropos of a case].
Bryois C; Rubin C; Zbinden JD; Baumann P
Praxis (Bern 1994); 1998 Mar; 87(10):345-8. PubMed ID: 9545842
[TBL] [Abstract][Full Text] [Related]
76. Hypertension, tachycardia, and reversible cardiomyopathy temporally associated with milnacipran use.
Forman MB; Sutej PG; Jackson EK
Tex Heart Inst J; 2011; 38(6):714-8. PubMed ID: 22199446
[TBL] [Abstract][Full Text] [Related]
77. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247
[TBL] [Abstract][Full Text] [Related]
78. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
79. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
80. Antidepressant discontinuation: a review of the literature.
Lejoyeux M; Adès J
J Clin Psychiatry; 1997; 58 Suppl 7():11-5; discussion 16. PubMed ID: 9219488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
